Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

More Than Stress Hyperglycemia: Acute Pancreatitis as a Prelude to Diabetes.

Diabetes care·2026
Same author

Pregnancies Affected by Diabetes in Teenagers and Emerging Adults: A Population-Based Study.

Metabolic syndrome and related disorders·2026
Same author

Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion.

American journal of physiology. Endocrinology and metabolism·2026
Same author

Hepatic steatosis in humans is associated with preserved glucagon action on amino acid metabolism.

The Journal of clinical investigation·2025
Same author

Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions.

American journal of physiology. Regulatory, integrative and comparative physiology·2025
Same author

Cardiovascular autonomic neuropathy defined by indices of heart rate variability is associated with cardiovascular disease: a longitudinal cohort study of participants with type 1 diabetes.

Cardiovascular diabetology·2025
Same journal

A Pilot Study on Disposal Practices and Environmental Awareness of Insulin-Related Devices Among People With Diabetes.

Journal of diabetes science and technology·2026
Same journal

Quality of In-Use Insulin Under Real-World Storage Conditions in Mwanza, Tanzania.

Journal of diabetes science and technology·2026
Same journal

Continuous Glucose Monitoring Metrics for Predicting Adverse Neonatal Outcomes in Individuals Undergoing Gestational Diabetes Screening.

Journal of diabetes science and technology·2026
Same journal

Diabetes Technologist: Optimal Use of Technology in Everyday Practice.

Journal of diabetes science and technology·2026
Same journal

AI-Driven Diabetes Care and Its Relevance in the Philippine Context: Opportunities and Persistent Digital Barriers.

Journal of diabetes science and technology·2026
Same journal

Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.

Journal of diabetes science and technology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Pharmacogenetics for type 2 diabetes: practical considerations for study design.

Adrian Vella1

  • 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA. vella.adrian@mayo.edu

Journal of Diabetes Science and Technology
|February 11, 2010
PubMed
Summary
This summary is machine-generated.

Identifying genetic variations influencing diabetes pharmacotherapy response requires careful study design. Researchers must consider nongenetic factors, disease stage, and appropriate genetic variants for accurate pharmacogenetic effect detection.

Related Experiment Videos

Last Updated: Jun 16, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Area of Science:

  • Pharmacogenomics
  • Metabolic Diseases
  • Clinical Pharmacology

Background:

  • Limited research exists on genetic variations impacting diabetes pharmacotherapy response.
  • Nongenetic variables, disease stage, and prior treatments significantly affect drug efficacy.
  • Selecting appropriate genetic variants and response measures is crucial for pharmacogenetic studies.

Purpose of the Study:

  • To highlight the need for comprehensive study designs in pharmacogenetic research for diabetes.
  • To emphasize the importance of considering various factors influencing treatment response.
  • To propose a strategic approach for future pharmacogenetic investigations in diabetes.

Main Methods:

  • Review of existing literature on diabetes pharmacogenetics.
  • Identification of key variables influencing treatment response.
  • Proposal for study design considerations, including population selection and outcome measures.

Main Results:

  • Lack of studies elucidating genetic factors in diabetes drug response.
  • Identification of critical nongenetic and disease-related confounders.
  • Recommendations for selecting common functional genetic variants and robust response measures.

Conclusions:

  • Future pharmacogenetic studies require meticulous design, accounting for genetic and nongenetic factors.
  • Smaller, homogenous population studies with surrogate markers may precede larger trials.
  • Standardized approaches are needed to advance understanding of diabetes pharmacogenetics.